Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Total Non-current Liabilities

All obligations due after more than one year.

SanofiNASDAQ: SNY

Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total non-current liabilities rises 7.6% from a year ago

Total non-current liabilities stood at €27.56B at the end of Q2 FY2026, up 7.6% from a year earlier and up 10.8% from the prior quarter. Over 3 fiscal years it compounded at -1.0% a year.

Context

  • Total non-current liabilities amounted to 21.4% of total assets at the end of Q2 FY2026, up 0.9 pp from a year earlier.
  • Total non-current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +7.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€27.56B+10.8% QoQ
Last fiscal yearDec 2025
€26.75B+3.8% YoY
Year agoJun 2025
€25.62B+7.6% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year+3.8%——
3-year CAGR-1.0%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

EUR · from the balance sheet

Latest · FY2025
26.75B EUR
Year-over-year change
+3.8%
4-year CAGR
-2.8%

Total Non-current Liabilities vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +7.6% is the 5th highest of 11, against a peer median of +6.7%.
  • Total non-current liabilities amounts to 21.4% of total assets for SNY, versus a peer median of 41.9%.
SNY Competitors
Total Non-current Liabilities for SNY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 134.58B DKK+26.3%+53.5%22.6%
PFEPfizer Inc.Jun 2026$82.99B USD+4.6%+12.6%41.3%
LLYEli Lilly and CompanyJun 2026$60.66B USD+39.3%+33.0%42.6%
MRKMerck & Co., Inc.Jun 2026$60.09B USD+41.6%+12.9%46.3%
AMGNAmgen Inc.Jun 2026$58.45B USD-2.6%+7.2%61.1%
NVSNovartis AGJun 2026$48.34B USD+57.8%+12.4%39.6%
BMYBristol-Myers Squibb CompanyJun 2026$46.66B USD-6.0%+3.2%53.2%
AZNAstraZeneca PLCSep 2026$36.78B USD+6.8%+1.6%30.7%
SNYSanofiJun 2026€27.56B EUR+7.6%-1.0%21.4%
GILDGilead Sciences, Inc.Jun 2026$26.6B USD+6.6%-7.2%53.9%
GSKGSK plcJun 2026£22.89B GBP-31.9%-4.6%37.3%
Peer median (excluding SNY) —+6.7%+9.8%41.9%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents10.1B12.74B8.71B7.44B7.66B
Short-term Investments000486M810M
Net Receivables9.79B10.75B11.04B10.63B11.05B
Inventory8.72B8.96B9.67B9.43B10.21B
Other Current Assets1.35B870M471M13.71B307M
Total Current Assets30.56B34.03B30.66B42.59B30.95B
Property, Plant & Equipment (Net)11.98B11.68B11.81B11.6B11.51B
Goodwill48.06B49.89B49.4B43.38B41.3B
Intangible Assets21.41B21.64B24.32B22.63B26.26B
Long-term Investments2.91B3.22B3.26B3.26B6.61B
Tax Assets4.6B5.38B6.43B7.97B8.61B
Other Non-current Assets731M882M588M1.37B1.56B
Total Non-current Assets89.68B92.7B95.81B90.21B95.85B
Total Assets120.24B126.72B126.46B132.8B126.81B
Account Payables6.18B6.81B7.33B7.55B7.36B
Short-term Debt3.45B4.45B2.32B4.21B4.34B
Tax Payables309M574M597M1.13B0
Deferred Revenue319M264M000
Other Current Liabilities10.61B11.86B11.57B15.13B14.69B
Total Current Liabilities21.3B23.96B24.19B29.16B28.35B
Long-term Debt17.12B14.86B14.35B11.79B14.25B
Deferred Tax Liabilities1.62B1.84B1.86B2.17B1.67B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities9.34B9B9.96B10.18B9.37B
Total Non-current Liabilities29.92B27.61B27.92B25.78B26.75B
Total Liabilities51.21B51.57B52.11B54.94B55.1B
Common Stock2.53B2.52B2.53B2.53B2.44B
Retained Earnings63.01B66.73B67.5B00
Accumulated OCI3.55B6.11B4.88B70.56B64.44B
Other Stockholders Equity0005.26B5.57B
Minority Interest350M368M313M350M334M
Total Equity69.03B75.15B74.35B77.86B71.71B
Total Debt22.41B21.21B18.7B17.91B20.33B
Net Debt12.32B8.48B9.99B10.47B12.67B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.